The 1-Adrenoceptor Subtype- and Protein Kinase C Isoform-dependence of Norepinephrine's Actions in Cardiomyocytes

Author: Rohde S.   Sabri A.   Kamasamudran R.   Steinberg S.F.  

Publisher: Academic Press

ISSN: 0022-2828

Source: Journal of Molecular and Cellular Cardiology, Vol.32, Iss.7, 2000-07, pp. : 1193-1209

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Catecholamines modulate cardiac function at least in part through 1-adrenergic receptors linked to the activation of protein kinase C (PKC). This study examines the molecular forms of the1-receptor and PKC that mediate norepinephrine's actions in cardiomyocytes; distinct approaches (activation-dependent down-regulation of PKC isoforms) and novel reagents (A61603, an 1A/c-receptor agonist) are used to resolve this issue which has been the focus of dispute in previous studies. Norepinephrine (NE) induces a rise in diacylglycerol levels which is sustained for 24 h and is associated with the translocation (at 5 min) and down-regulation (at 24 h) of PKC &dgr; and PKC &xgr; (but not PKC ). The selective targeting of the1-adrenergic receptor to activate novel PKC isoforms is remarkable, given an 8-fold greater abundance of PKC relative to PKC &xgr; in this preparation. NE activates the extracellular signal-regulated protein kinase (ERK) subfamily of mitogen-activated protein kinases through a PKC &dgr;/PKC &xgr; -dependent pathway. WB-4101 (1A/c- and 1D-receptor antagonist) and 5-methylurapidil (1A/c-receptor antagonist) inhibit norepinephrine-dependent accumulation of inositol phosphate and diacylglycerol, down-regulation of PKC &dgr; and PKC &xgr;, and activation of ERK. Each of these responses is stimulated by A61603, but not attenuated by high concentrations of chloroethylclonidine (which irreversibly inactivates the1B-, and to a lesser extent, the 1D-receptor) or BMY 7378 (selective1D-receptor antagonist). A61603 also activates p38-MAPK and induces hypertrophy. These studies establish that NE's actions in cardiomyocytes can be attributed to the 1A/c-adrenergic receptor subtype and nPKC isoforms, thereby identifying specific targets for the development of pharmaceuticals to influence cardiac contractile function and/or growth responses.

Related content